Intranasal administration of temozolomide for brain-targeting delivery: therapeutic effect on glioma in rats.
- Author:
Ying LI
1
;
Yongliang GAO
;
Gang LIU
;
Xiudi ZHOU
;
Yan WANG
;
Yulin WANG
;
Lin MA
Author Information
- Publication Type:Journal Article
- MeSH: Administration, Intranasal; Animals; Antineoplastic Agents, Alkylating; administration & dosage; Apoptosis; Brain Neoplasms; drug therapy; Cell Line, Tumor; Dacarbazine; administration & dosage; analogs & derivatives; Drug Delivery Systems; Glioma; drug therapy; Magnetic Resonance Imaging; Neoplasm Transplantation; Rats; Rats, Wistar
- From: Journal of Southern Medical University 2014;34(5):631-635
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo study the therapeutic effect of intranasal administration of temozolomide (TMZ) for brain-targeting delivery in a rat model bearing orthotopic C6 glioma xenografts.
METHODSForty Wistar rat bearing brain C6 glioma xenograft were randomly divided into 4 groups and treated with physiological saline solution or with TMZ by intravenous injection, gavage or intranasal administration. The tumor size, rat survival time and pathological changes were observed in each group.
RESULTSMagnetic resonance imaging showed a significantly reduced volume of glioma in intranasal TMZ group compared with that in the control, intraveneous TMZ injection group and TMZ gavage groups (12.45∓2.49 mm(3) vs 60.16∓4.12, 33.17∓3.56, and 35.16∓4.36 mm(3), respectively, P<0.05). The median survival time of the C6 glioma-bearing rats was also significantly longer in intranasal TMZ group than in the other 3 groups (31.0 days vs 20, 19, and 21.5 days, respectively, P<0.05). In the glioma xenografts, PCNA expression was the lowest and tumor cell apoptosis rate the highest in intranasal TMZ group.
CONCLUSIONIntranasal TMZ administration can suppress the growth of C6 glioma in rats and may serve as an effective strategy for glioma treatment.
